9amHealth Raises $26M to Expand Into Chronic Conditions Driving the Majority of Employer Pharmacy Spend

9amHealth, a prominent virtual specialty care platform, has successfully secured $26 million in Series B funding to enhance its AI-driven services aimed at high-cost chronic conditions. The funding round, announced on May 13, 2026, was led by Define Ventures, with participation from SemperVirens VC, Catalio Capital Management, and NewHealth Ventures. This capital injection will enable 9amHealth to expand its offerings beyond its established focus on cardiometabolic care, addressing chronic conditions that represent a significant portion of employer healthcare expenditures.

Since its inception in 2021, 9amHealth has positioned itself as a leader in virtual cardiometabolic care, collaborating with major enterprise employers and pharmaceutical companies to support individuals with obesity, diabetes, hypertension, and hyperlipidemia. The platform has demonstrated its efficacy by generating over $50 million in projected medical and pharmacy savings across two Fortune 100 employers. This success underscores the company's integrated care model, which combines clinical protocols, laboratory services, medication management, and continuous patient engagement to improve health outcomes while managing costs.

The strategic rationale behind this funding is to leverage 9amHealth's existing infrastructure and technology to manage a broader range of high-cost chronic conditions. These conditions, which account for up to 70% of employer pharmacy spend, require ongoing specialty medications and coordinated care, making them a critical focus for employers seeking to control healthcare costs. By extending its platform to include these additional chronic conditions, 9amHealth aims to capture a larger share of the market, which is increasingly prioritizing cost-effective and efficient healthcare solutions.

The participation of notable investors such as Define Ventures, led by Lynne O'Keefe, highlights the confidence in 9amHealth's potential to transform employer healthcare management. O'Keefe's involvement on the company's Board of Directors further solidifies the strategic partnership, as 9amHealth seeks to scale its operations and enhance its service delivery. The emphasis on AI-enabled clinical workflows and personalized member experiences positions 9amHealth to effectively address the complexities of chronic care management.

In the broader context, this funding round reflects a growing trend in the healthcare sector, where virtual care solutions are increasingly recognized for their ability to deliver specialized care while reducing costs. As employers face rising healthcare expenditures, platforms like 9amHealth that combine technology with clinical expertise are well-positioned to meet the demands of the market. The successful completion of this Series B funding round not only strengthens 9amHealth's financial foundation but also underscores the potential for innovation in managing chronic conditions, ultimately benefiting both employers and patients alike.